StockMacro
Menu

Spyre Therapeutics

$93.47 +27% in 6 monthsMarket cap $8.9B

SYRE on XNAS, Health Care, Spyre Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 298% in a year, but 12% of shares are sold short and the 12-month loss is $263.9M.

  • GoodNew institutional positions reached 64, 3.2 times the year-earlier level
  • BadInsiders sold $12.3M in 90 days and bought nothing

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Industry
Pharmaceutical preparations (Health Care)
Employees
130
Website
spyre.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $96.1M.
Quarter to 31 Dec 2021: revenue $3.6M, net income -$20.4MQuarter to 31 Dec 2021: revenue $3.6M, net income -$20.4MQuarter to 31 Mar 2022: revenue $1.4M, net income -$24.4MQuarter to 31 Mar 2022: revenue $1.4M, net income -$24.4MQuarter to 30 Jun 2022: revenue $625K, net income -$22.3MQuarter to 30 Jun 2022: revenue $625K, net income -$22.3MQuarter to 30 Sep 2022: revenue $174K, net income -$18.2MQuarter to 30 Sep 2022: revenue $174K, net income -$18.2MQuarter to 31 Dec 2022: revenue $168K, net income -$18.8MQuarter to 31 Dec 2022: revenue $168K, net income -$18.8MQuarter to 31 Mar 2023: revenue $198K, net income -$18.4MQuarter to 31 Mar 2023: revenue $198K, net income -$18.4MQuarter to 30 Jun 2023: revenue $688K, net income -$217.1MQuarter to 30 Jun 2023: revenue $688K, net income -$217.1MQuarter to 30 Sep 2023: revenue $0, net income -$40.1MQuarter to 30 Sep 2023: revenue $0, net income -$40.1MQuarter to 31 Dec 2023: revenue –, net income -$63.2MQuarter to 31 Mar 2024: revenue $0, net income -$43.9MQuarter to 31 Mar 2024: revenue $0, net income -$43.9MQuarter to 30 Jun 2024: revenue $0, net income -$38.8MQuarter to 30 Jun 2024: revenue $0, net income -$38.8MQuarter to 30 Sep 2024: revenue $0, net income -$69.0MQuarter to 30 Sep 2024: revenue $0, net income -$69.0MQuarter to 31 Dec 2024: revenue $0, net income -$56.3MQuarter to 31 Dec 2024: revenue $0, net income -$56.3MQuarter to 31 Mar 2025: revenue –, net income -$44.8MQuarter to 30 Jun 2025: revenue –, net income -$36.7MQuarter to 30 Sep 2025: revenue –, net income -$11.2MQuarter to 31 Dec 2025: revenue –, net income -$62.5MQuarter to 31 Mar 2026: revenue –, net income -$69.0MQuarter to 30 Jun 2026: revenue –, net income -$36.2MQuarter to 30 Sep 2026: revenue –, net income -$96.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $217.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$96.1M
30 Jun 2026–-$36.2M
31 Mar 2026–-$69.0M
31 Dec 2025–-$62.5M
30 Sep 2025–-$11.2M
30 Jun 2025–-$36.7M
31 Mar 2025–-$44.8M
31 Dec 2024$0-$56.3M
30 Sep 2024$0-$69.0M
30 Jun 2024$0-$38.8M
31 Mar 2024$0-$43.9M
31 Dec 2023–-$63.2M
30 Sep 2023$0-$40.1M
30 Jun 2023$688K-$217.1M
31 Mar 2023$198K-$18.4M
31 Dec 2022$168K-$18.8M
30 Sep 2022$174K-$18.2M
30 Jun 2022$625K-$22.3M
31 Mar 2022$1.4M-$24.4M
31 Dec 2021$3.6M-$20.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$263.9M -$149.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -35.0% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.1B $486.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.1B (net cash) -$486.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $11.07
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 8.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Spyre TherapeuticsSYRE (this company) $8.9Bloss–––
Madrigal PharmaceuticalsMDGL $8.8Bloss6.2+93%-10.9%
Praxis Precision MedicinesPRAX $8.4Bloss–––
TG TherapeuticsTGTX $9.6B90.310.7+69%11.8%
Summit TherapeuticsSMMT $8.0Bloss–––
Protagonist TherapeuticsPTGX $7.9B23.214.4+164%62.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$12.3M

bought $0, sold $12.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.2%

285 13F filers vs 261

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

101.1M shares held by 13F filers (30 Sep 2026) of 95.0M outstanding (27 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

11.6M shares sold short (30 Oct 2026) of 95.0M outstanding (27 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

12.7

11.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.1%

12.5M shares sold short in the report before, 11.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

5

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$70K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

22

22 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.3×

22 articles in the last 7 days; its usual week has 3.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 64, 3.2× a year earlier

Price $93.47 on 20 Nov 2026, +298% over 12 months (12-month range $23.47 to $109.00)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $441.9M in the last 12 months (the 12 months before: -$1.3M).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 285 13F filers reported holding it in the latest 13F quarter, +118% on a year earlier.
Lobbying spend. Lobbying spend: $70K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 64 vs usual 26 (2026-09-30); 3.2x the same period a year earlier
29 May 20268-K and other filingsDirector or officer change
29 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 47 vs usual 25.50 (2026-03-31); 2.5x the same period a year earlier
17 Nov 2025Lobbying filingnew lobbying registration (ARNOLD & PORTER KAYE SCHOLER LLP)
6 Mar 20258-K and other filingsChanged its auditor
18 Nov 20248-K and other filingsEarlier financial statements can no longer be relied on
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 48 vs usual 7.50 (2024-03-31); 48.0x the same period a year earlier
15 May 20248-K and other filingsDirector or officer change
15 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Apr 20248-K and other filingsRegistered new securities for sale (S-1)
26 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
14 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
1 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
5 Feb 20248-K and other filingsDirector or officer change
3 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
18 Jan 20248-K and other filingsDelisting notice or listing transfer
27 Dec 20238-K and other filingsPrivate placement of securities (Form D)
22 Dec 20238-K and other filingsRegistered new securities for sale (S-1)
28 Nov 20238-K and other filingsDirector or officer change
15 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
7 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
7 Oct 20238-K and other filingsDirector or officer change
25 Sep 20238-K and other filingsDirector or officer change
25 Sep 20238-K and other filingsDelisting notice or listing transfer
5 Sep 20238-K and other filingsDirector or officer change
11 Aug 20238-K and other filingsA major agreement ended
27 Jul 20238-K and other filingsA major agreement ended
27 Jul 20238-K and other filingsCompleted an acquisition or asset sale
14 Jul 20238-K and other filingsDelisting notice or listing transfer
6 Jul 20238-K and other filingsPrivate placement of securities (Form D)
23 Jun 20238-K and other filingsDirector or officer change
23 Jun 20238-K and other filingsCompleted an acquisition or asset sale
19 May 20238-K and other filingsDirector or officer change
21 Apr 2023Lobbying filinglobbying engagement terminated (THE KPM GROUP DC LLC)
12 Apr 20238-K and other filingsRestructuring costs announced
12 Apr 20238-K and other filingsDirector or officer change
12 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jan 20238-K and other filingsDelisting notice or listing transfer
6 Jan 20238-K and other filingsDirector or officer change
30 Nov 20228-K and other filingsDirector or officer change
30 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Aug 20228-K and other filingsDirector or officer change
19 Jul 20228-K and other filingsDelisting notice or listing transfer
7 Jul 20228-K and other filingsDirector or officer change
7 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Mar 20228-K and other filingsDirector or officer change
10 Feb 20228-K and other filingsDirector or officer change
14 Dec 2021Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 935K)
Insider net buying (open market)
Month from 1 Dec 2021: $935K published
Month from 1 Mar 2022: $624K published
Month from 1 Jun 2022: $20K published
Month from 1 Aug 2022: $50K published
Month from 1 Sep 2024: -$522K published
Month from 1 Oct 2024: -$11K published
Month from 1 Nov 2024: -$246K published
Month from 1 Sep 2025: -$300K published
Month from 1 Nov 2025: -$1.0M published
Month from 1 Dec 2025: -$435K published
Month from 1 Jan 2026: -$460K published
Month from 1 Feb 2026: -$492K published
Month from 1 Mar 2026: -$734K published
Month from 1 Apr 2026: -$1.5M published
Month from 1 May 2026: -$13.5M published
Month from 1 Jun 2026: -$405.2M published
Month from 1 Jul 2026: -$2.7M published
Month from 1 Aug 2026: -$4.6M published
Month from 1 Sep 2026: -$6.1M published
Month from 1 Oct 2026: -$6.3M published
Revenue per quarter
Quarter ended 31 Dec 2021: $3.6M; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $1.4M; public on 6 May 2022
Quarter ended 30 Jun 2022: $625K, -95% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $174K, -88% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $168K, -95% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $198K, -85% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $688K, +10% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Capital spending per quarter
Quarter ended 31 Mar 2022: $37K, -92% on a year earlier; public on 6 May 2022
Quarter ended 30 Sep 2022: $1K, -99% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2023: $0; public on 1 Mar 2024
Institutional holders (13F filers)
31 Dec 2021 report: 78; public on 14 Feb 2022
31 Mar 2022 report: 79; public on 16 May 2022
30 Jun 2022 report: 63; public on 15 Aug 2022
30 Sep 2022 report: 52; public on 14 Nov 2022
31 Dec 2022 report: 51; public on 14 Feb 2023
31 Mar 2023 report: 43; public on 15 May 2023
30 Jun 2023 report: 42; public on 14 Aug 2023
30 Sep 2023 report: 27; public on 14 Nov 2023
31 Dec 2023 report: 52; public on 14 Feb 2024
31 Mar 2024 report: 98; public on 15 May 2024
30 Jun 2024 report: 106; public on 14 Aug 2024
30 Sep 2024 report: 115; public on 14 Nov 2024
31 Dec 2024 report: 129; public on 14 Feb 2025
31 Mar 2025 report: 127; public on 15 May 2025
30 Jun 2025 report: 126; public on 14 Aug 2025
30 Sep 2025 report: 131; public on 14 Nov 2025
31 Dec 2025 report: 151; public on 17 Feb 2026
31 Mar 2026 report: 193; public on 15 May 2026
30 Jun 2026 report: 261; public on 14 Aug 2026
30 Sep 2026 report: 285; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Jul 2022: $20K published
Quarter from 1 Oct 2022: $30K published
Quarter from 1 Jan 2023: $30K published
Quarter from 1 Apr 2023: $30K published
Quarter from 1 Jan 2026: $10K published
Quarter from 1 Apr 2026: $40K published
Quarter from 1 Jul 2026: $10K published
Quarter from 1 Oct 2026: $10K published

What is unusual now

  • Made public in the last 90 days: it saw 64 13F filers open a new position in the quarter ended 30 Sep 2026, 3.2× the same quarter last year.
  • Many funds opening a new position: saw 64 13F filers open a new position in the quarter ended 30 Sep 2026, 3.2× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $441.9M in the last 12 months (the 12 months before: -$1.3M).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 61 insider trades

Last 90 days: 6 sales, $12.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Oct 2026Heidy King-JonesSee RemarksSellplanned in advance (10b5-1); after exercising options28,933$91.03$2.6MForm 4
2 Oct 2026Cameron TurtleChief Executive OfficerSellplanned in advance (10b5-1)15,000$92.01$1.4MForm 4
2 Oct 2026Scott L BurrowsChief Financial OfficerSellplanned in advance (10b5-1); after exercising options25,000$90.47$2.3MForm 4
3 Sep 2026Scott L BurrowsChief Financial OfficerSellplanned in advance (10b5-1); after exercising options25,732$88.75$2.3MForm 4
3 Sep 2026Cameron TurtleChief Executive OfficerSellplanned in advance (10b5-1)15,000$87.29$1.3MForm 4
3 Sep 2026Heidy King-JonesSee RemarksSellplanned in advance (10b5-1); after exercising options28,399$87.35$2.5MForm 4
10 Aug 2026Jeffrey W. AlbersDirectorSellplanned in advance (10b5-1); after exercising options23,000$104.53$2.4MForm 4
5 Aug 2026Scott L BurrowsChief Financial OfficerSellplanned in advance (10b5-1); after exercising options7,500$95.57$717KForm 4

285 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 64 opened a position, 41 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)13.5M14.2%$1.2B+470K+3.6%
BlackRock, Inc.6.8M7.14%$603.6M+273K+4.2%
Paradigm Biocapital Advisors LP4.5M4.69%$396.8M+617K+16%
Vanguard Portfolio Management LLC4.1M4.28%$361.8M+1.7M+74%
Vanguard Capital Management LLC3.8M3.95%$333.9M+302K+8.8%
RTW Investments, LP3.7M3.89%$328.7M-560K-13%
State Street Corp3.5M3.72%$314.6M+476K+16%
Perceptive Advisors LLC3.3M3.45%$292.1M-1.0M-24%
T. Rowe Price Associates Inc3.0M3.20%+76K+2.6%
Janus Henderson Group Ltd.2.9M3.05%$257.8M

Company events

All 81 company events

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
7 Oct 2026Signed a major agreement8-K
29 May 2026Director or officer changeSame filing: shareholder vote results8-K
16 Apr 2026Signed a major agreement8-K
15 Oct 2025Signed a major agreement8-K
6 Mar 2025Changed its auditor8-K
19 Nov 2024Signed a major agreement8-K
18 Nov 2024Earlier financial statements can no longer be relied on8-K
15 Oct 2024Signed a major agreement8-K

5 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 60%, Operations & administration 20%, Research & science 20%.

PostedJobLocation
10 Nov 2026Clinical Scientist, Clinical DevelopmentResearch & scienceUS- Remote
6 Nov 2026Senior Director, Intellectual Property CounselLegal, policy & complianceUS- Remote
30 Oct 2026Director, Regulatory AffairsLegal, policy & complianceUS- Remote
30 Sep 2026Director, Drug Safety PhysicianLegal, policy & complianceUS- Remote
25 Sep 2026Senior Director, Drug Safety and Pharmacovigilance OperationsOperations & administrationUS- Remote

Reported lobbying spend: $10K in Q3 2026, $10K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
7 Nov 2025NewArnold & Porter Kaye Scholer LLPfor Spyre Therapeutics, Inc.FDA policies relating to monoclonal antibody products.MED, Pharmacy, Health issuesFiling
31 Mar 2023EndedThe KPM Group DC LLCfor Aeglea Biotherapeutics, Inc.Not statedFiling
15 May 2020NewThe KPM Group DC LLCfor Aeglea Biotherapeutics, Inc.Priority Review Vouchers and Biomedical Advanced Research and Development Authority (BARDA) engagementPharmacyFiling

The 5 newest of 159 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 64 13F filers open a new position in the quarter ended 30 Sep 2026, 3.2× the same quarter last year.

    Same quarter last year: 20; its normal quarter is 26.

    See the evidence
    This period
    64 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    26
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +3.9
    Same quarter last year
    20
    History used
    3,744 days
    2024-09-30: 272024-12-31: 252025-03-31: 192025-06-30: 182025-09-30: 202025-12-31: 272026-03-31: 472026-06-30: 842026-09-30: 64
    the quarter ended 30 Sep 20268 earlier quartersnormal: 26

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 29 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 29 May 2026Filings record

    Director or officer change

  4. 15 May 2026Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 31 Mar 2026, 2.5× the same quarter last year.

    Same quarter last year: 19; its normal quarter is 25.5.

    See the evidence
    This period
    47 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    25.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.1
    Same quarter last year
    19
    History used
    3,561 days
    2024-03-31: 482024-06-30: 262024-09-30: 272024-12-31: 252025-03-31: 192025-06-30: 182025-09-30: 202025-12-31: 272026-03-31: 47
    the quarter ended 31 Mar 20268 earlier quartersnormal: 25.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 17 Nov 2025Lobbying record

    SPYRE THERAPEUTICS, INC.: new lobbying registration (ARNOLD & PORTER KAYE SCHOLER LLP) (dated 7 Nov 2025)

  6. 6 Mar 2025Filings record

    Changed its auditor

  7. 18 Nov 2024Filings record

    Earlier financial statements can no longer be relied on

  8. 15 May 2024Institutional holdings change

    saw 48 13F filers open a new position in the quarter ended 31 Mar 2024, 48× the same quarter last year.

    Same quarter last year: 1; its normal quarter is 7.5.

    See the evidence
    This period
    48 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +6.1
    Same quarter last year
    1
    History used
    2,831 days
    2022-03-31: 62022-06-30: 122022-09-30: 52022-12-31: 92023-03-31: 12023-06-30: 122023-09-30: 32023-12-31: 262024-03-31: 48
    the quarter ended 31 Mar 20248 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 15 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 15 May 2024Filings record

    Director or officer change

  11. 19 Apr 2024Filings record

    Registered new securities for sale (S-1) (dated 18 Apr 2024)

  12. 26 Mar 2024Filings record

    Registered new securities for sale (S-1)

  13. 14 Mar 2024Filings record

    Registered new securities for sale (S-1)

  14. 1 Mar 2024Filings record

    Registered new securities for sale (S-1)

  15. 5 Feb 2024Filings record

    Director or officer change

  16. 3 Feb 2024Filings record

    Registered new securities for sale (S-1) (dated 2 Feb 2024)

  17. 18 Jan 2024Filings record

    Delisting notice or listing transfer

  18. 27 Dec 2023Filings record

    Private placement of securities (Form D) (dated 26 Dec 2023)

  19. 22 Dec 2023Filings record

    Registered new securities for sale (S-1)

  20. 28 Nov 2023Filings record

    Director or officer change

  21. 15 Nov 2023Filings record

    Registered new securities for sale (S-1)

  22. 7 Oct 2023Filings record

    Registered new securities for sale (S-1) (dated 6 Oct 2023)

  23. 7 Oct 2023Filings record

    Director or officer change (dated 6 Oct 2023)

  24. 25 Sep 2023Filings record

    Director or officer change

  25. 25 Sep 2023Filings record

    Delisting notice or listing transfer

  26. 5 Sep 2023Filings record

    Director or officer change

  27. 11 Aug 2023Filings record

    A major agreement ended

  28. 27 Jul 2023Filings record

    Completed an acquisition or asset sale

  29. 27 Jul 2023Filings record

    A major agreement ended

  30. 14 Jul 2023Filings record

    Delisting notice or listing transfer

  31. 6 Jul 2023Filings record

    Private placement of securities (Form D)

  32. 23 Jun 2023Filings record

    Director or officer change

  33. 23 Jun 2023Filings record

    Completed an acquisition or asset sale

  34. 19 May 2023Filings record

    Director or officer change

  35. 21 Apr 2023Lobbying record

    AEGLEA BIOTHERAPEUTICS, INC.: lobbying engagement terminated (THE KPM GROUP DC LLC) (dated 31 Mar 2023)

  36. 12 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 12 Apr 2023Filings record

    Director or officer change

  38. 12 Apr 2023Filings record

    Restructuring costs announced

  39. 18 Jan 2023Filings record

    Delisting notice or listing transfer

  40. 6 Jan 2023Filings record

    Director or officer change

Showing the newest 40 of 98 entries; narrow the window or the kind of data to see older ones.

Not listed: 197 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001636282
Ticker
SYRE
Domain
spyre.com
Hq location
MA|WALTHAM|02453 (1 unverified)
Lobbying client
aeglea biotherapeutics, spyre therapeutics
Name
Aeglea BioTherapeutics, Inc., Document, EX-21.1, ex211-subsidiariesofspyret.htm and 2 more
Wikidata
Q45133036
  • Federal lobbying disclosures (LDA)3 records, 48 data points15 May 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings378 data points30 Jun 2016 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)216 records14 Mar 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)730 data points31 Dec 2013 to 27 Oct 2026
  • SEC Form 4 insider transactions61 records, 160 data points12 Apr 2016 to 2 Oct 2026
  • FINRA short interest (twice monthly)213 data points30 Nov 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1498 data points28 Nov 2023 to 20 Nov 2026